GSK plc (NYSE:GSK) Shares Purchased by Cypress Wealth Services LLC

Cypress Wealth Services LLC grew its holdings in shares of GSK plc (NYSE:GSK) by 23.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 11,966 shares of the pharmaceutical company’s stock after buying an additional 2,301 shares during the quarter. Cypress Wealth Services LLC’s holdings in GSK were worth $405,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the business. FMR LLC boosted its position in GSK by 8.3% during the 3rd quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock worth $1,185,885,000 after purchasing an additional 2,224,345 shares during the period. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in shares of GSK in the second quarter worth about $52,487,000. Fisher Asset Management LLC grew its stake in shares of GSK by 4.9% in the third quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock valued at $759,425,000 after buying an additional 870,449 shares in the last quarter. Hotchkis & Wiley Capital Management LLC grew its stake in shares of GSK by 30.8% in the third quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company’s stock valued at $144,803,000 after buying an additional 833,080 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in shares of GSK by 33.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,256,320 shares of the pharmaceutical company’s stock valued at $86,875,000 after buying an additional 569,614 shares during the period. Institutional investors and hedge funds own 15.74% of the company’s stock.

Wall Street Analysts Forecast Growth

GSK has been the subject of several recent research reports. Deutsche Bank Aktiengesellschaft downgraded shares of GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Guggenheim downgraded shares of GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. StockNews.com upgraded GSK from a “buy” rating to a “strong-buy” rating in a research note on Monday. Finally, Jefferies Financial Group cut GSK from a “buy” rating to a “hold” rating and cut their price target for the stock from $53.00 to $39.50 in a research note on Tuesday, November 12th. Seven research analysts have rated the stock with a hold rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $43.25.

GSK Trading Up 2.1 %

Shares of GSK stock opened at $33.50 on Friday. GSK plc has a 1 year low of $31.72 and a 1 year high of $45.92. The firm has a market capitalization of $69.42 billion, a PE ratio of 21.75, a price-to-earnings-growth ratio of 1.44 and a beta of 0.63. The stock has a fifty day moving average of $34.14 and a two-hundred day moving average of $38.04. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.53 and a current ratio of 0.81.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, January 9th. Stockholders of record on Friday, November 15th were paid a $0.3928 dividend. The ex-dividend date of this dividend was Friday, November 15th. This represents a $1.57 annualized dividend and a dividend yield of 4.69%. This is a boost from GSK’s previous quarterly dividend of $0.38. GSK’s payout ratio is currently 96.10%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.